Yes, Novo Nordisk raised its 2026 outlook for the third time this year after its Wegovy weight loss pill beat sales forecasts in the third quarter. The Danish drugmaker said on November 4, 2026 that the pill brought in 5.39 billion Danish kroner, about 810 million dollars, in the quarter, up 53 percent from the second quarter and well above the 4.62 billion kroner analysts had expected. The company now expects 2026 adjusted sales and adjusted operating profit to land between a 2 percent decline and 2 percent growth at constant exchange rates, up from its earlier range of a 6 percent decline to flat growth.
Quick Facts
| Company | Novo Nordisk, Danish drugmaker |
| Announcement date | November 4, 2026 |
| Wegovy pill Q3 sales | 5.39 billion Danish kroner (about 810 million dollars) |
| Pill sales vs forecast | Above the 4.62 billion kroner consensus estimate |
| Pill sales growth | Up 53 percent from the second quarter of 2026 |
| New 2026 outlook | Adjusted sales and operating profit between minus 2 percent and plus 2 percent |
| Previous 2026 outlook | Between minus 6 percent and flat growth |
| Outlook raises in 2026 | Third raise this year |
| Q3 adjusted sales | 79.20 billion kroner, up 4 percent at constant exchange rates |
| Q3 adjusted operating profit | 31.72 billion kroner, up 27 percent at constant exchange rates |
| Q3 reported net profit | 16.74 billion kroner, down 16 percent |
| Pill rollout plan | More than 20 countries by mid-2027, ahead of the end-2027 target |
| US oral market share | About 80 percent of new-to-brand prescriptions |
Why the Wegovy Pill Beat Expectations
The Wegovy pill was the star of Novo Nordisk’s third quarter. Sales of the oral treatment reached 5.39 billion kroner, compared with analyst expectations of about 4.62 billion kroner, according to Reuters. That is a beat of roughly 20 percent, and it came in a quarter when the pill was still in the early stages of its rollout. The pill launched in the United States in January 2026, and it is now sold in eight markets, including the United States, the United Kingdom, Germany and the United Arab Emirates.
The growth was fast. Pill sales rose 53 percent from the second quarter to the third quarter, and prescriptions reached about 3.6 million in the quarter. Since launch, prescriptions for the pill have passed 8 million. Novo estimates the pill holds about 80 percent of new-to-brand prescriptions in the United States across reimbursed, cash-pay and telehealth channels. That is a strong position in a market where the company is fighting to win back ground lost to its main rival, Eli Lilly, over the past two years.
What the Raised Outlook Actually Means
Novo raised its full-year forecast for adjusted sales and adjusted operating profit to a range of minus 2 percent to plus 2 percent at constant exchange rates. The previous range, set in August, was minus 6 percent to flat. That is a meaningful upgrade, and it is the third time the company has raised its outlook in 2026.
The upgrade reflects higher expectations for sales of its GLP-1 medicines in both of its operating units. Third-quarter sales rose 4 percent at constant exchange rates to 79.2 billion kroner, beating a FactSet estimate of 73.6 billion kroner. Adjusted operating profit rose 27 percent at constant exchange rates to 31.72 billion kroner, above the 28.39 billion kroner analysts had projected. Obesity drug sales climbed 22 percent to 26.1 billion kroner in the quarter.
There is an important distinction in the numbers. The improved guidance uses adjusted measures, which strip out exceptional and non-recurring items. Reported operating profit actually fell 3 percent in Danish kroner and 9 percent at constant exchange rates, and reported quarterly net profit fell 16 percent to 16.74 billion kroner. The company said stronger expectations for GLP-1 product sales support the revised outlook, but it still expects lower realized prices and intensifying competition to weigh on the business. Earnings season has produced several big beats this week, including our report on AppLovin and its record third-quarter revenue.
The Pill Versus the Injection
Not every part of the Wegovy franchise is growing. Sales of injectable Wegovy fell 13 percent in the United States at constant exchange rates in the quarter, although combined United States Wegovy sales rose 21 percent once the pill is included. Injectable Wegovy generated 20.41 billion kroner in the quarter, down 2 percent at constant exchange rates. Ozempic, the diabetes version of the same drug, contributed 29.7 billion kroner, above expectations.
The shift from injection to pill is part of the story. Some patients who would have started on the injection are now starting on the pill instead, and Novo says the pill accounts for more than half of new patient starts among branded obesity drugs. Management also said growth in pill prescriptions has flattened recently, which it attributed to seasonality rather than a loss of demand. That is a point investors will watch closely in the fourth quarter, because a pill that stalls after a fast start would change the growth story.
The competition is not standing still. Eli Lilly has been gaining share in the obesity market, and Novo has said it expects lower prices and tougher competition to continue, including pressure in the United States and the loss of semaglutide exclusivity in some international markets. The pill gives Novo a product its rival does not yet match at the same scale, but the advantage depends on keeping the rollout on schedule and the price competitive.
Faster Rollout and Lower Prices Ahead
Novo said high manufacturing output and faster approvals from health authorities had allowed it to speed up the rollout of the Wegovy pill. It now plans to launch the pill in more than 20 countries by mid-2027, compared with the end-2027 target it gave at its capital markets day in September. That is a faster timetable, and it matters because international markets are where Novo expects sales to grow while United States sales decline.
Price is the other big change coming. Starting January 1, 2027, Novo will lower the United States list price of Wegovy and Ozempic, including their pill versions, to 675 dollars, cuts of about 50 percent and 35 percent respectively. The move follows the company’s most-favored-nation agreement with the United States administration, and it reflects the political pressure on drug prices that has shaped the market all year. Lower prices should help more patients afford the drugs, but they will also squeeze revenue per patient, which is why volume growth matters so much to the outlook.
The company is also preparing to launch CagriSema, its next obesity drug, in the United States early in 2027, subject to regulatory approval. Citi kept a neutral rating on the stock after the results, pointing to continued uncertainty over near, mid and long-term pricing of weight-loss drugs and the lack of a clear Wegovy successor in the pipeline. Big health care companies are reshaping themselves this year, as seen in our report on CVS Health splitting into two companies by 2028.
What the Chief Executive Said, and What Changed at the Top
Chief Executive Mike Doustdar was careful not to declare victory. He told CNBC that one strong quarter does not establish a turnaround, saying recovery is not done based on one data point. That caution is worth noting, because Novo has raised its outlook three times this year and still faces the same pressures that caused the slump: pricing, competition and the cost of building the pill business.
There was also a leadership change in the results. Chief Financial Officer Karsten Munk Knudsen will leave at the end of 2026 after 27 years at the company, nine of them as chief financial officer. A new finance chief will inherit a company that is growing again on an adjusted basis but still working through the gap between its adjusted numbers and its reported profit.
For patients, the news is simpler. A pill version of a popular weight loss drug is selling fast, reaching more countries sooner than planned, and its United States price is set to fall sharply in January. The usual caution applies to any weight loss medicine: this is general information, not medical advice, and anyone considering a GLP-1 drug should talk to their own doctor about whether it is right for them, what the side effects can be, and what it costs under their own coverage. Chip and technology earnings have also been strong this quarter, including our report on Arm Holdings and its record second-quarter revenue.
Frequently Asked Questions
How much did the Wegovy pill sell in the third quarter?
The Wegovy pill brought in 5.39 billion Danish kroner, about 810 million dollars, in the third quarter of 2026. That was up 53 percent from the second quarter and above the 4.62 billion kroner consensus estimate from analysts. Prescriptions reached about 3.6 million in the quarter and have passed 8 million since the pill launched in the United States in January.
What is Novo Nordisk’s new outlook for 2026?
Novo now expects 2026 adjusted sales and adjusted operating profit to each land between a 2 percent decline and 2 percent growth at constant exchange rates. The previous range, set in August, was a decline of up to 6 percent to flat growth. This is the third time the company has raised its outlook in 2026.
How many countries will get the Wegovy pill?
The pill is now sold in eight markets, including the United States, the United Kingdom, Germany and the United Arab Emirates. Novo plans to launch it in more than 20 countries by mid-2027, which is faster than the end-2027 target it gave in September. High manufacturing output and faster approvals from health authorities made the faster timetable possible.
Why did reported profit fall if the outlook improved?
Reported quarterly net profit fell 16 percent to 16.74 billion kroner, and reported operating profit fell 9 percent at constant exchange rates. The improved guidance uses adjusted measures that exclude exceptional and non-recurring items. Adjusted operating profit rose 27 percent at constant exchange rates to 31.72 billion kroner. The gap between the two sets of numbers is why the chief executive warned that one strong quarter does not prove a turnaround.
Sources
This article is based on reporting from Reuters, CNBC, Invezz and Novo Nordisk. The Reuters report is available at Global Banking and Finance, the Invezz report is available at Invezz, and the Novo Nordisk financial report is available at Novo Nordisk.
Final Thoughts
Novo Nordisk’s third quarter gave the company its best news in a long while. The Wegovy pill sold 5.39 billion kroner, beat forecasts by about 20 percent, and pushed the company to raise its 2026 outlook for the third time this year. The rollout is accelerating to more than 20 countries by mid-2027, and the United States list price is set to fall to 675 dollars in January. The cautions are real too: reported profit fell, the injection business is shrinking in the United States, and the chief executive himself says one quarter does not make a turnaround. But for a company that spent two years sliding, a beat this clear is a genuine change of direction.
